Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;60(6):727-739.
doi: 10.1007/s40262-020-00982-z. Epub 2021 Jan 30.

A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients

Philip Roland Selby  1   2 , Sepehr Shakib  3   4 , Sandra L Peake  3   5 , Morgyn S Warner  3   6   7 , David Yeung  3   7   8   9 , Uwe Hahn  3   7   8 , Jason A Roberts  10   11   12
Affiliations

A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients

Philip Roland Selby et al. Clin Pharmacokinet. 2021 Jun.

Abstract

Background: Ganciclovir (GCV) and valganciclovir (VGCV) are the first-line agents used to prevent and treat cytomegalovirus (CMV) infection in allogeneic haematopoietic stem cell transplant (alloHCT) patients.

Objective: The aim of this work was to describe available data for the clinical pharmacokinetics, pharmacodynamics and toxicodynamics of GCV and VGCV and the potential of a therapeutic drug monitoring strategy to improve outcomes in the alloHCT population.

Methods: We systematically reviewed the pharmacokinetics (dose-exposure), pharmacodynamics (exposure-efficacy) and toxicodynamics (exposure-toxicity) of GCV and VGCV in alloHCT patients with CMV infection. Studies including alloHCT patients treated for CMV infection reporting the pharmacokinetics, pharmacodynamics and toxicodynamics of GCV or VGCV were searched for using the PUBMED and EMBASE databases from 1946 to 2019. Only studies involving participants > 12 years of age and available in the English language were included.

Results: A total of 179 patients were included in the 14 studies that met the inclusion criteria, of which 6 examined GCV pharmacokinetics only, while 8 also examined GCV pharmacodynamics and toxicodynamics. Reported pharmacokinetic parameters showed considerable interpatient variability and were different from other populations, such as solid organ transplant and human immunodeficiency virus-infected patients. Only one study found a correlation between neutropenia and elevated peak and trough GCV concentrations, with no other significant pharmacodynamic and toxicodynamic relationships identified. While therapeutic drug monitoring of GCV is performed in some institutions, no association between GCV therapeutic drug monitoring and clinical outcomes was identified.

Conclusion: Further studies of the pharmacokinetics, pharmacodynamics and toxicodynamics of GCV/VGCV in alloHCT patients are required to identify a more robust therapeutic range and to subsequently quantify the potential value of therapeutic drug monitoring of GCV/VGCV in the alloHCT population.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Li J, Smith A, Crouch S, Oliver S, Roman E. Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN). Cancer Causes Control. 2016;27(8):1019–26. - PubMed - PMC
    1. Australian Bureau of Statistics. Australia's leading causes of death 2018. Australian Bureau of Statistics. https://www.abs.gov.au/ausstats/abs@.nsf/PrimaryMainFeatures/3302.0?Open... . Accessed Dec 2019.
    1. Nivison-Smith I, Bardy P, Dodds AJ, Ma DDF, Aarons D, Tran S, et al. A review of hematopoietic cell transplantation in Australia and New Zealand, 2005 to 2013. Biol Blood Marrow Transplant. 2016;22(2):284–91. https://doi.org/10.1016/j.bbmt.2015.09.009 . - DOI - PubMed
    1. Nivison-Smith I, Bradstock KF, Dodds AJ, Hawkins PA, Szer J. Haemopoietic stem cell transplantation in Australia and New Zealand, 1992–2001: progress report from the Australasian Bone Marrow Transplant Recipient Registry. Intern Med J. 2005;35(1):18–27. - PubMed
    1. Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters. Blood Rev. 2017;31(3):173–83. https://doi.org/10.1016/j.blre.2017.01.002 . - DOI - PubMed

Publication types

MeSH terms